Equities
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nexus AG is a Germany-based company. The Company is engaged in the development, trade and service of software solutions for facilities of the healthcare system. It is divided into three divisions: NEXUS/ DE (Germany), NEXUS/ DIS (Diagnostic systems) and NEXUS/ ROE (Rest of Europe). The Company has different product groups such as: NEXUS/ HISng, an information system for somatic hospitals in Germany; NEXUS/ PSYCHIATRY, an information system for psychiatric institutions; NEXUS/ REHAng, an information system for rehabilitation facilities; NEXUS/ ITR, a software for rehabilitation, private, acute care clinics not providing surgery and hotels with medical care; NEXUS/ ARCHIVE and NEXUS/ PEGASOS, provides archiving and process management in healthcare, among others.

  • Revenue in EUR (TTM)261.00m
  • Net income in EUR26.77m
  • Incorporated1999
  • Employees1.85k
  • Location
    Nexus AGIrmastrasse 1DONAUESCHINGEN 78166GermanyDEU
  • Phone+49 771229600
  • Fax+49 77 122960999
  • Websitehttps://www.nexus-ag.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NXUX:GER since
announced
Transaction
value
OpenLISDeal completed07 Nov 202407 Nov 2024Deal completed-0.29%--
Data delayed at least 15 minutes, as of Nov 25 2024 16:36 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.